

Please add the following new claims. These claims correspond to claims 68-70, 72, 74(partially), and 75(partially) as originally filed.

Sub
Ch
B²
118.(new) The isolated nucleic acid molecule of claim 67, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

B²
119.(new) The isolated nucleic acid molecule of claim 67, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

120.(new) The isolated nucleic acid molecule of claim 67, wherein the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

Sub
Ch
121.(new) An expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 2 molecule.

122.(new) A host cell transformed or transfected with an expression vector of claims 121.

123.(new) A host cell transformed or transfected with an expression vector of claim 121 and further comprising a nucleic acid encoding HLA.


-3-

Remarks

Applicants have amended claim 71 and added new claims 118-123. Applicants also canceled a number of claims. The number of claims that will be pending after this amendment does not exceed the number previously paid for, and therefore no additional claims fees are due.

Support for the amendment to claim 71 and the new claims can be found in the claims as originally filed. No new matter has been added.

Respectfully submitted,


John R. Van Amsterdam, Reg. No. 40,212
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Docket No.: L0461/7078
Date: November 30, 2000
X12/03/01

578829_1

Nov 30 2001 15:33 P.10

Fax:6177202441

WOLF GREENFIELD

-4-

Amended Claim

71.(twice amended) An expression vector comprising an isolated nucleic acid molecule of claim [59] 67 operably linked to a promoter.

578829_1

Nov 30 2001 15:33 P. 11

Fax:6177202441

WOLF GREENFIELD